Prospective Cohort Study of Felzartamab in Rituximab-Resistant Primary Membranous Nephropathy

Introduction: Approximately 30% of patients with primary membranous nephropathy (MN) and nephrotic syndrome (NS) fail rituximab treatment through mechanisms that could be overcome by the human IgG1 monoclonal anti-CD38 antibody, felzartamab. Methods: In this prospective, single-arm, single-center, o...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Matias Trillini, Federica Casiraghi, Alessia Gennarini, Valentina Portalupi, Maddalena Marasà, Manuel Alfredo Podestà, Silvia Prandini, Silvia Nozza, Marta Todeschini, Francesco Pecoraro, Marilena Mister, Fabiola Carrara, Nadia Stucchi, Tobia Peracchi, Diego Fidone, Alessandro Villa, Nadia Rubis, Olimpia Diadei, Davide Martinetti, Giuseppe Remuzzi, Piero Ruggenenti
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2026-06-01
Edice:	Kidney International Reports
Témata:	anti-CD38 antibodies felzartamab membranous nephropathy nephrotic syndrome rituximab
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2468024926027002
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!